Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,788Revenue $M596Net Margin (%)8.4Z-Score10.5
Enterprise Value $M2,345EPS $0.8Operating Margin %12.6F-Score6
P/E(ttm))58.6Cash Flow Per Share $1.3Pre-tax Margin (%)12.9Higher ROA y-yN
Price/Book3.210-y EBITDA Growth Rate %0Quick Ratio3.9Cash flow > EarningsY
Price/Sales5.05-y EBITDA Growth Rate %23.5Current Ratio4.4Lower Leverage y-yY
Price/Cash Flow16.5y-y EBITDA Growth Rate %-60.8ROA % (ttm)4.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)5.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M71.3ROI % (ttm)18.6Gross Margin Increase y-yY

Gurus Latest Trades with IPXL

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
IPXLJoel Greenblatt 2014-12-31 Add0.01%$23.63 - $32.75
($29.4)
$ 39.0833%Add 136.17%79,609
IPXLMario Gabelli 2014-12-31 Buy $23.63 - $32.75
($29.3)
$ 39.0833%New holding, 6775 sh.6,775
IPXLNWQ Managers 2014-12-31 Reduce-0.1%$23.63 - $32.75
($29.3)
$ 39.0833%Reduce -30.25%906,043
IPXLNWQ Managers 2014-09-30 Add0.08%$22.77 - $30.68
($25.55)
$ 39.0853%Add 31.9%1,298,995
IPXLJoel Greenblatt 2014-09-30 Buy 0.01%$22.77 - $30.68
($25.55)
$ 39.0853%New holding, 33709 sh.33,709
IPXLJohn Hussman 2014-09-30 Reduce-0.14%$22.77 - $30.68
($25.55)
$ 39.0853%Reduce -19.35%250,000
IPXLNWQ Managers 2014-06-30 Buy 0.3%$23.6 - $30.68
($26.93)
$ 39.0845%New holding, 984841 sh.984,841
IPXLJohn Hussman 2014-06-30 Add0.21%$23.6 - $30.68
($26.93)
$ 39.0845%Add 40.91%310,000
IPXLJohn Hussman 2014-03-31 Buy 0.44%$22.02 - $27.91
($24.94)
$ 39.0857%New holding, 220000 sh.220,000
IPXLJohn Hussman 2012-03-31 Sold Out -0.11%$18.64 - $24.37
($20.72)
$ 39.0889%Sold Out0
IPXLJoel Greenblatt 2012-03-31 Sold Out -0.05%$18.64 - $24.37
($20.72)
$ 39.0889%Sold Out0
IPXLJoel Greenblatt 2011-12-31 Reduce-0.47%$16.53 - $20.75
($18.65)
$ 39.08110%Reduce -88.51%21,057
IPXLJoel Greenblatt 2011-09-30 Reduce-0.38%$15.26 - $21.56
($19.54)
$ 39.08100%Reduce -40.22%183,187
IPXLJoel Greenblatt 2011-06-30 Add0.76%$20.21 - $28.73
($25.28)
$ 39.0855%Add 446.09%306,452
IPXLGeorge Soros 2011-06-30 Sold Out $20.21 - $28.73
($25.28)
$ 39.0855%Sold Out0
IPXLJohn Hussman 2011-03-31 Add0.02%$20.11 - $25.52
($22.84)
$ 39.0871%Add 20.21%339,000
IPXLGeorge Soros 2011-03-31 Reduce$20.11 - $25.52
($22.84)
$ 39.0871%Reduce -41.13%13,600
IPXLJoel Greenblatt 2011-03-31 Reduce-1.55%$20.11 - $25.52
($22.84)
$ 39.0871%Reduce -78.32%56,118
IPXLJoel Greenblatt 2010-12-31 Buy 1.7%$17.91 - $21.86
($19.9)
$ 39.0896%New holding, 258801 sh.258,801
IPXLJohn Hussman 2010-12-31 Add0.06%$17.91 - $21.86
($19.9)
$ 39.0896%Add 176.47%282,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

IPXL is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
IPXL Mario Gabelli 2014-12-316,7750.010New Buy
IPXL Joel Greenblatt 2014-12-3179,6090.110.02+136.17%
IPXL John Hussman 2014-12-31250,0000.350.79
IPXL NWQ Managers 2014-12-31906,0431.270.34-30.25%
Premium Most recent portfolio changes are included for Premium Members only!


IPXL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HSU LARRYDirector 2014-06-06Sell100,000$28.3841.23view
TERRERI PETER RDirector 2014-05-27Sell3,000$2843.14view
HSU LARRYDirector 2014-05-22Sell50,000$27.2247.24view
HSU LARRYDirector 2014-05-21Sell3,800$26.5351.07view
TERRERI PETER RDirector 2014-05-20Sell666$26.0753.74view
TERRERI PETER RDirector 2014-05-19Sell950$26.0353.98view
FLEMING NIGELDirector 2014-05-16Sell1,900$25.7255.83view
TERRERI PETER RDirector 2014-05-13Sell666$26.750.11view
FLEMING NIGELDirector 2014-05-12Sell1,333$26.5850.79view
MARKBREITER MICHAELDirector 2014-05-08Sell12,500$26.4451.59view

Press Releases about IPXL :

    Quarterly/Annual Reports about IPXL:

    News about IPXL:

    Articles On GuruFocus.com
    Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
    comment on IPXL Sep 24 2012 
    President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
    Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 
    Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 10,000 Shares Aug 12 2010 
    Impax Laboratories Reports Second Quarter 2009 Financial Results Aug 04 2009 


    More From Other Websites
    Actavis' Xydalba Granted Marketing Authorisation in Europe - Analyst Blog Mar 03 2015
    The oil selloff created this buying opportunity Feb 26 2015
    JPM Securities Picks Through Biotech News For Winners Feb 25 2015
    Pacira Misses Earnings Estimates in Q4, Revenues In Line - Analyst Blog Feb 25 2015
    Impax to Present at the Cowen and Company 35th Annual Health Care Conference Feb 25 2015
    Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog Feb 24 2015
    Will Allscripts (MDRX) Surprise Earnings Estimates in Q4? - Analyst Blog Feb 24 2015
    Impax Labs tops Street 4Q forecasts Feb 24 2015
    Impax Labs tops Street 4Q forecasts Feb 24 2015
    IMPAX LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 24 2015
    Assembly Biosciences (ASMB) in Focus: Stock Falls 7.4% - Tale of the Tape Feb 24 2015
    Q4 2014 Impax Laboratories Inc Earnings Release - Before Market Open Feb 24 2015
    Impax Revenues Increased 30% to $131 Million in Fourth Quarter 2014 Feb 24 2015
    Will Celldex Therapeutics (CLDX) Disappoint This Earnings? - Analyst Blog Feb 23 2015
    Pfizer Rapamune Under FDA Priority Review for Lung Disease - Analyst Blog Feb 23 2015
    Will BioMarin (BMRN) Beat Estimates this Earnings Season? - Analyst Blog Feb 23 2015
    Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog Feb 23 2015
    Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog Feb 23 2015
    What's in Store for Endocyte (ECYT) this Earnings Season? - Analyst Blog Feb 20 2015
    Can Greatbatch (GB) Keep the Earnings Streak Alive in Q4? - Analyst Blog Feb 20 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK